

Fig. 1









Fig. 2a

*Type III Cer-1-TBDMS**C2 Cer-1-TBDMS**C6 Cer-1-TBDMS**C2 Cer-1-TBDPS*


664207-16962460

Fig. 2b




662201-16962460

Fig. 2c




1-Acetate-3-one C6-Cer.




4,5-Diol C6-Cer


Fig. 2d



N-Hexyl Sphingosine (or N-C8 Sphingosine)




N-C8 Sphingosine




N-C10 Sphingosine

Fig. 3




09429694-102793

Fig. 4




09429694-102799

Fig. 5



09429694-102799

Fig. 6



1562201-16362460

Fig. 7




Fig. 8




Fig. 9A

In Vitro Sensitivity of A549 to C6-Ceramide Derivatives After
One Hour Drug Exposure




Fig. 9B

In Vitro Sensitivity of A549 to C6-Ceramide Derivatives After
Four Hour Drug Exposure




Fig. 9C

In Vitro Sensitivity of A549 to C6-Ceramide Derivatives After
Eight Hour Drug Exposure




Fig. 9D

***In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After
24 Hour Drug Exposure**




Fig. 9E

In Vitro Sensitivity of A549 to C6-Ceramide Derivatives After
48 Hour Drug Exposure




Fig. 10

In Vitro Sensitivity of A549 to 1-Acetate C6-Ceramide at
Different Exposure Times




Fig. 11




Fig. 12

In Vitro Sensitivity of A549 to 1-Isobutyrate C6-Ceramide at
Different Exposure Times





Fig. 13

In Vitro Sensitivity of A549 to N-C8 Sphingosine at Different Exposure Times



Therapeutic efficacy of N-C6-Sphingosine
against P-388/ADR tumor bearing mice

Fig. 14

